Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease
about
Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's diseaseOral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's diseaseTraditional corticosteroids for induction of remission in Crohn's diseaseEnteral nutrition for maintenance of remission in Crohn's diseaseProbiotics for maintenance of remission in Crohn's diseaseInterventions for growth failure in childhood Crohn's diseaseVedolizumab for the treatment of ulcerative colitis and Crohn's diseaseVedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel diseaseCrohn's disease: a clinical updateOptimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug WithdrawalEvidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in JapanProbiotics in inflammatory bowel diseases and associated conditionsPharmacogenetics in inflammatory bowel diseaseSearching for the delta: 5-aminosalicylic Acid therapy for Crohn's diseaseConventional therapy for Crohn's diseaseIndications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?European evidence based consensus on the diagnosis and management of Crohn's disease: current management.Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe GroupManagement of Crohn's disease - are guidelines transferred to clinical practice?Management of inflammatory bowel diseases in Eastern EuropeEvaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease.Treatment of inflammatory bowel disease: a review of medical therapy.Second Korean guidelines for the management of Crohn's disease.Anti-tumour necrosis factor-alpha therapies in Crohn's disease.Consensus guidelines for the management of inflammatory bowel disease.Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.The role of enteral nutrition in patients with inflammatory bowel disease: current aspects.Asia-Pacific consensus statements on Crohn's disease. Part 2: Management.Risk Stratification of Patients with Crohn's Disease: A Retrospective Analysis of Clinical Decision Making and Its Impact on Long-Term Outcome.Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease.Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel diseaseSubgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease.Evidence-based clinical practice guidelines for inflammatory bowel disease.A PRObabilistic Pathway Score (PROPS) for Classification with Applications to Inflammatory Bowel Disease.Inflammatory Bowel Disease.
P2860
Q24234938-C8728250-0B89-4DF6-8D9E-466E52FDDB4EQ24239841-3860B1EA-5708-4D9C-BB84-3790340BA74BQ24242955-83B63B8F-B83E-4FE0-9A99-AF641540B705Q24243835-AFB8F5F0-EFFF-4902-BE7E-F118522A03B1Q24244110-27F7AA0F-4B34-468E-BDCA-A4AEB07BFACEQ24246404-43903333-5880-4857-A3D3-F1F7A74D2125Q24630083-E0116AF0-52BC-41CC-8394-B10B344C163AQ26752768-7AECD29B-2733-4D84-94A0-B183735ECC21Q26777696-F347F1D3-BEB4-483B-AE5C-D84C54D953AAQ26801119-5916C587-B631-4A86-B5D7-57AE35D2C222Q26829392-1F8EC63C-6F9C-4368-A3B0-10B96DAFF2C2Q27002496-D723236E-327E-4A7F-95A6-6222A8307C86Q28246002-EC9DAEE2-F7F4-4E25-9265-2D412CB20FC8Q28390019-753914EB-B802-44D4-8155-0F9B354A5AA4Q33866982-54E2806C-5F65-421A-A269-65EB499B6112Q33868970-473FD63E-CD22-481E-9CC3-2AB4478C0936Q34564902-69EE2E1E-6CE3-42F6-8D09-EF73E39C887CQ35013983-E5669024-F63D-413C-8DDC-E62D88A8C9B5Q35926094-0A87FF46-EE56-4E93-9DB9-02EAC00A5C00Q36441778-D9B4AFA9-8EE6-4F4E-A87E-1E6873CF8D9DQ36470212-5462A027-C426-4FE6-AB54-2704350B8680Q37058862-5BA1C227-BE40-462D-8E8F-D48F01F5E310Q37662498-94CBF8EA-5520-481E-8949-A0083F688FDAQ37676831-6C1C520C-385E-442E-AC6C-958C283D6AA9Q37817803-A9EE9F14-A579-4D78-92E6-5B5AD884343BQ37892884-04D9A7F3-ABFC-46BC-9885-FF6282110968Q38385101-7ABDF25F-FA25-47E4-92F0-7E0CF79EA305Q38394726-BE0A6F91-09C6-4BD3-A9D8-6D2DD4D5A0CDQ38706667-B89D0355-C284-4384-AD49-212189BD5543Q38967059-8DD5907F-3799-44A2-8B8F-0D517284C111Q41891210-1703397B-1356-4F46-A818-BF6EE2E71EE5Q44781843-71C52509-7E0B-411C-9A19-ADBB67E537A5Q50079201-0008E2BF-8DDA-4897-9C8D-7DE85CC31C21Q50094730-2890F9C1-35B4-4407-B13C-DD9EB7CD0171Q53241323-4F597E6D-4075-4619-8457-78E50B29F16A
P2860
Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Oral 5-aminosalicylic acid for ...... d remission in Crohn's disease
@ast
Oral 5-aminosalicylic acid for ...... d remission in Crohn's disease
@en
Oral 5-aminosalicylic acid for ...... d remission in Crohn's disease
@en-gb
Oral 5-aminosalicylic acid for ...... d remission in Crohn's disease
@nl
type
label
Oral 5-aminosalicylic acid for ...... d remission in Crohn's disease
@ast
Oral 5-aminosalicylic acid for ...... d remission in Crohn's disease
@en
Oral 5-aminosalicylic acid for ...... d remission in Crohn's disease
@en-gb
Oral 5-aminosalicylic acid for ...... d remission in Crohn's disease
@nl
prefLabel
Oral 5-aminosalicylic acid for ...... d remission in Crohn's disease
@ast
Oral 5-aminosalicylic acid for ...... d remission in Crohn's disease
@en
Oral 5-aminosalicylic acid for ...... d remission in Crohn's disease
@en-gb
Oral 5-aminosalicylic acid for ...... d remission in Crohn's disease
@nl
P2860
P1476
Oral 5-aminosalicylic acid for ...... d remission in Crohn's disease
@en
P2093
Anthony K Akobeng
Elizabeth Gardener
P2860
P356
10.1002/14651858.CD003715.PUB2
P577
2005-01-24T00:00:00Z